$2 / month

Comment and reply across TML.

Start or manage membership

Most pulsed

Advertisement Sinscents Bad Intentions. Great Candles.

Latest from other desks

tml.the modern leap
Money / Business

Seawolf Surfaces With $100 Million and a $1.2 Billion Sanofi Ceiling

Seawolf Therapeutics came out of stealth on Monday, November 16, with $100 million raised and a Sanofi collaboration worth up to $1.2 billion in milestone payments. The San Diego company delivers DNA into cell nuclei with fat particles instead of viruses. Only one of those two numbers is money in hand, and it isn't the bigger one.

A researcher at work in a laboratory (archive). Photo: James Gathany, CDC, public domain, via Wikimedia Commons.
Summary

Seawolf has $100 million in the bank today. The $1.2 billion is a ceiling Sanofi pays only if the science works, target by target, over years.

Tap a passage. React to the part that matters.

Seawolf Therapeutics emerged from stealth on Monday, November 16, with $100 million raised and a research collaboration with Sanofi that could pay out up to $1.2 billion. The two numbers aren't the same kind of money. The $100 million is financing the San Diego company has closed. The $1.2 billion is a ceiling of research, development and commercial milestone payments, plus tiered royalties, that Sanofi owes only if programs hit their marks. The deal also carries an upfront payment, and Chief Executive Elizabeth Alcamo declined to tell Reuters how much it is.

The financing came in two piles. Versant Ventures led a seed round, and a Series A followed backed by Versant, MPM BioImpact and the Novartis Venture Fund, with participation from Eli Lilly, CRISPR Therapeutics, Sixty Degree Capital, Alexandria Venture Investments and Pathway to Cures, the venture arm of the National Bleeding Disorders Foundation. When Lilly, CRISPR Therapeutics and a Novartis fund all sit on the same cap table, the syndicate is itself a signal about which delivery problem the industry wants solved.

The problem is the virus. Most gene therapies ride into cells inside a modified virus, and a patient's immune system learns to recognize that ride, which makes a second dose hard or impossible. Seawolf's platform, called TRIDENT, skips the virus. It uses a lipid nanoparticle, a tiny ball of fat, to carry a proprietary DNA structure into the nucleus of a cell, with an auxiliary factor protein in the same payload that helps the DNA get read once it's inside. The company says the system is redosable, meaning a patient could receive it more than once.

The evidence so far is animal evidence. Seawolf says TRIDENT has produced sustained protein expression above therapeutic levels in primates at doses that were safe and well tolerated. No human has received it. The company expects to pick a drug candidate by late 2027 and file to begin human trials by the end of 2028, which puts the first patient data years away and the Sanofi milestones further out than that.

Four office chairs in a rowFor businessesAmazon Business is Amazon’s purchasing store for companies, with business accounts and quantity ordering.Register with Amazon Business

Sanofi's targets are undisclosed. The collaboration covers bleeding disorders and additional unnamed indications, under a multi-target research agreement with an exclusive license. Bleeding disorders are the natural first test for a DNA delivery platform because the therapeutic goal is measurable in the blood: get the body to produce a clotting factor it doesn't make, and the protein level either rises or it doesn't. Seawolf's own lead program sits elsewhere, in metabolic disease, and is advancing toward a development candidate. The company says that program builds muscle and reduces fat in animals, with possible uses in obesity, muscle loss and osteoporosis.

Alcamo, the company's founder, president and chief executive, holds a doctorate and built the pitch around delivery rather than around any single drug. That's the structure to watch. A platform company with $100 million, one internal program and a large partner's milestone schedule doesn't need a blockbuster next year. It needs its first candidate to survive contact with human biology, because every dollar above the upfront depends on that.

Sources

The conversation

A little more perspective.

Reading is free. Verified members can comment and reply for $2 a month.

The conversation.

Loading comments…

Keep your curiosity going.

Some links here are affiliate links. If you buy through one, we might make a commission — it never changes what you pay. As an Amazon Associate I earn from qualifying purchases.